Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 317 participants.

Also called NCT01233622

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 317 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01233622
Other papers using this trial's data
  • Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea Diabetes, obesity & metabolism, 2014-05 DOI, PubMed 24199686, PMC4237555 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, Germany, Hungary, Italy, Mexico, Philippines, Romania, South Korea, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01233622. Randomized; double masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2011-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride
Acronym
Vildagliptin
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Vildagliptin
Intervention (Drug)
Placebo
Lead sponsor
Novartis (class: industry)

Record details

Record id
cardio:ct-nct01233622
Content hash
1ea2830cb3df1fcdb8e4cc5c5a47659392f66ba3208b909797e9b7e707c6f4d0